(TEVA) Teva Pharma Industries - Ratings and Ratios
Generic Drugs, CNS Therapies, Respiratory Inhalers, Oncology Injections, OTC Creams
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 38.6% |
| Value at Risk 5%th | 51.6% |
| Relative Tail Risk | -18.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.09 |
| Alpha | 46.78 |
| CAGR/Max DD | 1.06 |
| Character TTM | |
|---|---|
| Hurst Exponent | |
| Beta | 0.877 |
| Beta Downside | 0.974 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.70% |
| Mean DD | 14.29% |
| Median DD | 12.06% |
Description: TEVA Teva Pharma Industries October 14, 2025
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a global generic-drug leader that also markets a range of branded specialty medicines. Its product slate spans tablets, capsules, injectables, inhalers, transdermal patches, and combination devices, with a strategic focus on central nervous system, respiratory, and oncology therapies. In addition to manufacturing active pharmaceutical ingredients (APIs) and offering contract-manufacturing services, Teva runs an out-licensing platform that monetizes its extensive product portfolio.
Key branded assets include COPAXONE for multiple sclerosis, AJOVY (migraine prevention), UZEDY (schizophrenia), and oncology injectables BENDEKA and TREANDA. The company also sells OTC products under brands such as SUDOCREM and FLEGAMINA, and maintains collaborations with partners like Sanofi, Alvotech, and MedinCell to augment its pipeline and distribution reach.
As of FY 2023, Teva reported revenue of roughly $13.5 billion, with a net debt-to-EBITDA ratio of ≈ 3.2, reflecting ongoing balance-sheet deleveraging. The generic market is pressured by US pricing reforms and biosimilar competition, but growth in specialty injectables and the CNS segment offers a higher-margin offset. Assuming the company can sustain its 2024-2025 pipeline launches and maintain cost-discipline, the upside potential hinges on market share gains in the respiratory inhaler space and successful commercialization of its oncology injectables. For a deeper quantitative assessment, you may find the analytics on ValueRay useful for benchmarking TEVA’s valuation against sector peers.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (712.0m TTM) > 0 and > 6% of Revenue (6% = 1.01b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -0.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.42% (prev -8.84%; Δ 16.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.41b > Net Income 712.0m (YES >=105%, WARN >=100%) |
| Net Debt (14.89b) to EBITDA (3.69b) ratio: 4.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.16b) change vs 12m ago 2.74% (target <= -2.0% for YES) |
| Gross Margin 50.09% (prev 49.84%; Δ 0.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.11% (prev 40.16%; Δ 0.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.80 (EBITDA TTM 3.69b / Interest Expense TTM 1.49b) >= 6 (WARN >= 3) |
Altman Z'' -1.06
| (A) 0.03 = (Total Current Assets 12.74b - Total Current Liabilities 11.49b) / Total Assets 39.86b |
| (B) -0.36 = Retained Earnings (Balance) -14.24b / Total Assets 39.86b |
| (C) 0.07 = EBIT TTM 2.67b / Avg Total Assets 40.81b |
| (D) -0.51 = Book Value of Equity -16.66b / Total Liabilities 32.60b |
| Total Rating: -1.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 54.06
| 1. Piotroski 2.0pt |
| 2. FCF Yield 2.15% |
| 3. FCF Margin 5.47% |
| 4. Debt/Equity 2.36 |
| 5. Debt/Ebitda 4.04 |
| 6. ROIC - WACC (= 1.57)% |
| 7. RoE 11.08% |
| 8. Rev. Trend 62.82% |
| 9. EPS Trend -14.25% |
What is the price of TEVA shares?
Over the past week, the price has changed by +8.56%, over one month by +31.30%, over three months by +43.41% and over the past year by +61.50%.
Is TEVA a buy, sell or hold?
- Strong Buy: 6
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TEVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.9 | 3.8% |
| Analysts Target Price | 27.9 | 3.8% |
| ValueRay Target Price | 34.4 | 27.8% |
TEVA Fundamental Data Overview November 25, 2025
P/E Trailing = 39.6885
P/E Forward = 8.5251
P/S = 1.6557
P/B = 3.8311
P/EG = 1.2934
Beta = 0.697
Revenue TTM = 16.78b USD
EBIT TTM = 2.67b USD
EBITDA TTM = 3.69b USD
Long Term Debt = 16.77b USD (from longTermDebt, last quarter)
Short Term Debt = 24.0m USD (from shortTermDebt, last quarter)
Debt = 17.09b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.89b USD (from netDebt column, last quarter)
Enterprise Value = 42.66b USD (27.78b + Debt 17.09b - CCE 2.20b)
Interest Coverage Ratio = 1.80 (Ebit TTM 2.67b / Interest Expense TTM 1.49b)
FCF Yield = 2.15% (FCF TTM 918.0m / Enterprise Value 42.66b)
FCF Margin = 5.47% (FCF TTM 918.0m / Revenue TTM 16.78b)
Net Margin = 4.24% (Net Income TTM 712.0m / Revenue TTM 16.78b)
Gross Margin = 50.09% ((Revenue TTM 16.78b - Cost of Revenue TTM 8.37b) / Revenue TTM)
Gross Margin QoQ = 51.43% (prev 50.34%)
Tobins Q-Ratio = 1.07 (Enterprise Value 42.66b / Total Assets 39.86b)
Interest Expense / Debt = 1.22% (Interest Expense 209.0m / Debt 17.09b)
Taxrate = 33.02% (214.0m / 648.0m)
NOPAT = 1.79b (EBIT 2.67b * (1 - 33.02%))
Current Ratio = 1.11 (Total Current Assets 12.74b / Total Current Liabilities 11.49b)
Debt / Equity = 2.36 (Debt 17.09b / totalStockholderEquity, last quarter 7.25b)
Debt / EBITDA = 4.04 (Net Debt 14.89b / EBITDA 3.69b)
Debt / FCF = 16.22 (Net Debt 14.89b / FCF TTM 918.0m)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.79% (Net Income 712.0m / Total Assets 39.86b)
RoE = 11.08% (Net Income TTM 712.0m / Total Stockholder Equity 6.43b)
RoCE = 11.53% (EBIT 2.67b / Capital Employed (Equity 6.43b + L.T.Debt 16.77b))
RoIC = 7.61% (NOPAT 1.79b / Invested Capital 23.54b)
WACC = 6.04% (E(27.78b)/V(44.87b) * Re(9.25%) + D(17.09b)/V(44.87b) * Rd(1.22%) * (1-Tc(0.33)))
Discount Rate = 9.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.18%
[DCF Debug] Terminal Value 77.62% ; FCFE base≈1.10b ; Y1≈1.35b ; Y5≈2.31b
Fair Price DCF = 27.48 (DCF Value 31.53b / Shares Outstanding 1.15b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -14.25 | EPS CAGR: 0.34% | SUE: 0.28 | # QB: 0
Revenue Correlation: 62.82 | Revenue CAGR: 2.39% | SUE: 0.81 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.58 | Chg30d=+0.020 | Revisions Net=+3 | Analysts=3
EPS current Year (2025-12-31): EPS=2.64 | Chg30d=+0.078 | Revisions Net=+3 | Growth EPS=+6.2% | Growth Revenue=+2.6%
EPS next Year (2026-12-31): EPS=2.83 | Chg30d=+0.005 | Revisions Net=+0 | Growth EPS=+6.9% | Growth Revenue=+0.2%
Additional Sources for TEVA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle